Tumour mutational burden and microsatellite instability are regarded as predictive biomarkers for immunotherapy.23, –25 In addition, a previous study revealed that patients with gastric cancer and higher tumour mutational burden scores had better survival outcomes.26 In the present study, TMEM119 was found to be significantly inversely associated with tumour mutational burden and patients with low tumour mutational burden and high TMEM119 had a poor prognosis, consistent with the abovementioned previous reports. The gene discussed is TMEM119; the disease is neoplasm.